Stay updated with breaking news from Aezs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright dropped their price objective on shares of Aeterna Zentaris from $2.00 to $1.50 and set a “buy” […]
Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.02), MarketWatch Earnings reports. Aeterna Zentaris had a negative net margin of 156.35% and a negative return on equity of 13.07%. Shares of AEZS […]
StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a report released on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Aeterna Zentaris stock opened at $0.37 on Friday. The business has a 50 day moving average of $0.36 and a 200-day moving average of $0.47. […]
Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism March 11, 2021 08:05 ET | Source: Aeterna Zentaris Inc Aeterna Zentaris Inc Montreal CANADA – Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary...